Iovance Biotherapeutics (IOVA) reported a third-quarter 2025 loss of 25 cents per share, beating estimates. Revenues rose 15% year over year to $67.5 million, driven by Amtagvi sales. Operating costs increased due to R&D expenses, but gross margins improved to 43%. Shares rose 28% post-earnings announcement.

Iovance reiterated its full-year product revenue guidance of $250 million to $300 million. The company expects growth in total product revenues for 2026 and beyond, with increased gross margins. Regulatory applications for Amtagvi in melanoma are under review in multiple countries.

Iovance announced a new study for Amtagvi in advanced melanoma. The company also reported positive interim data for the drug in non-small cell lung cancer. Shares of IOVA are down 69% year to date. Analysts recommend Alkermes, CorMedix, and ANI Pharmaceuticals as top picks in the biotech sector.

Read more at Nasdaq: IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y